An observational study in Covid 19, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.
Sponsored by University Hospital, Montpellier · Observational
As observed with SARS-CoV responsible for SARS 2003, the new coronarovirus SARS-CoV-2 uses the angiotensin converting enzyme type 2 (ACE2) as cellular receptor to infect cells. The renin aldosterone angiostensin system (RAAS) has known effects in the lungs: some receptors are pro-inflammatory, others are anti-inflammatory. Thus the deregulation of the RAAS induced by the SARS-CoV-2 could explain the inflammatory response of Covid-19 infection and be a modulator of the severity of its course.
Furthermore, the SARS 2003 experience suggests that there may be others endocrine involvment, particularly an failure on the hypothalamus-pituitary and adrenal axis. Indeeed, cases of hypocorticism and hypothyroidism of central origin were described.
Altogether, the endocrine system might play a role both in the pathophysiology of Covid-19 infection and in the activity and severity of the disease.
In this study, the investigators proposed to explore endocrine functions on biological samples in a series of patients admitted for Covid-19 in our clinic.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 50 is below the median of 260 across 3,135 observational studies indexed under COVID-19.
Browse COVID-19 studies →University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Covid-19 diagnosis hospitalized in Montpellier University hospital
Exclusion criteria:
Plasma aldosterone levels
Plasma aldosterone levels
Time frame: 1 day (at inclusion)
Plasma renin levels
Plasma renin levels
Time frame: 1 day (at inclusion)
covid-19 infection severity
covid-19 infection severity : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death).
Time frame: 1 day (at inclusion)
Maximum severity of Covid-19 infection
Maximum severity of Covid-19 infection using a seven-category ordinal scale at at the end of hospitalization : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death).
Time frame: 1 day (at inclusion)
Plasma aldosterone level
Plasma aldosterone level
Time frame: 1 day (at the end of hospitalization)
Plasma ACTH level
Plasma ACTH level
Time frame: 1 day (at the end of hospitalization)
Plasma cortisol level
Plasma cortisol level
Time frame: 1 day (at inclusion)
Plasma cortisol level
Plasma cortisol level
Time frame: 1 day (at the end of hospitalization)
Plasma T3l level
Plasma T3l level
Time frame: 1 day (at the end of hospitalization)
Plasma T3l level
Plasma T3l level
Time frame: 1 day (at inclusion)
Plasma ACTH level
Plasma ACTH level
Time frame: 1 day (at inclusion)
Plasma LH level
Plasma LH level
Time frame: 1 day (at inclusion)
Plasma LH level
Plasma LH level
Time frame: 1 day (at the end of hospitalization)
Plasma DHEA level
Plasma DHEA level
Time frame: 1 day (at the end of hospitalization)
Plasma DHEA level
Plasma DHEA level
Time frame: 1 day (at inclusion)
Plasma estradiol (female) or testosterone (male) level
Plasma estradiol (female) or testosterone (male) level
Time frame: 1 day (at the end of hospitalization)
Plasma estradiol (female) or testosterone (male) level
Plasma estradiol (female) or testosterone (male) level
Time frame: 1 day (at inclusion)
Plasma FSH level
Plasma FSH level
Time frame: 1 day (at the end of hospitalization)
Plasma FSH level
Plasma FSH level
Time frame: 1 day (at inclusion)
type of treatments
type of treatments
Time frame: 1 day
Clinical characteristics
Clinical characteristics extracted from electronic medical
Time frame: 1 day
radiological characteristics
radiological characteristics : quantification of the percentage of lesional damage to the pulmonary parenchyma
Time frame: 1 day
Plan to share: Undecided — NC
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier